A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 (IRAK1) Pathway Activation (PAIR)
Latest Information Update: 05 Jul 2023
At a glance
- Drugs Pacritinib (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms PAIR
- 25 Aug 2020 New trial record